Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia
NCT ID: NCT02087540
Last Updated: 2014-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
310 participants
INTERVENTIONAL
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan
NCT03872232
Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin
NCT03088254
Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia
NCT03566316
To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
NCT04659070
Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine
NCT04158076
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Telmisartan 80mg & Rosuvastatin 20mg
PO, Once Daily, 8 weeks
Telmisartan 80mg
Rosuvastatin 20mg
Placebo(for Rosuvastatin 10mg)
Telmisartan 80mg & Rosuvastatin 10mg
PO, Once Daily, 8weeks
Telmisartan 80mg
Rosuvastatin 10mg
Placebo(for Rosuvastatin 20mg)
Telmisartan placebo & Rosuvastatin 20mg
PO, Once Daily, 8 weeks
Rosuvastatin 20mg
Placebo(for Telmisartan 80mg)
Placebo(for Rosuvastatin 10mg)
Telmisartan Placebo & Rosuvastatin 10mg
PO, Once Daily, 8 weeks
Rosuvastatin 10mg
Placebo(for Telmisartan 80mg)
Placebo(for Rosuvastatin 20mg)
Telmisartan 80mg & Rosuvastatin placebo
PO, Once Daily, 8 weeks
Telmisartan 80mg
Placebo(for Telmisartan 80mg)
Placebo(for Rosuvastatin 20mg)
Telmisartan placebo & Rosuvastatin placebo
PO, Once Daily, 8 weeks
Placebo(for Telmisartan 80mg)
Placebo(for Rosuvastatin 20mg)
Placebo(for Rosuvastatin 10mg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Telmisartan 80mg
Rosuvastatin 20mg
Rosuvastatin 10mg
Placebo(for Telmisartan 80mg)
Placebo(for Rosuvastatin 20mg)
Placebo(for Rosuvastatin 10mg)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men and women \>18 years of age
* Subject who has one of 3 conditions classifed by Cardiovascular Risk Factors, 10-Year Risk, Blood Pressure, LDL-C, Coronary Artery Disease and Equivalent
Exclusion Criteria
* Other exclusions applied
19 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IlDong Pharmaceutical Co Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Catholic University of Saint Mary's Hosiptal
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID_Telotan_1203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.